

1 **Double trouble? When a pandemic and seasonal virus collide**

2 Casey Zipfel^{1*}, Vittoria Colizza², Shweta Bansal¹

3 ¹*Department of Biology, Georgetown University, Washington DC, USA*

4 ²*INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health,*
5 *Paris, France*

6 *Corresponding author: Casey Zipfel (cmz27@georgetown.edu), Shweta Bansal*

7 *(shweta.bansal@georgetown.edu)*

8 **Abstract**

9 As healthcare capacities in the US and Europe reach their limits due to a surge in the COVID-19
10 pandemic, both regions enter the 2020-2021 influenza season. Southern hemisphere countries
11 that had suppressed influenza seasons provide a hopeful example, but the lack of reduction in
12 influenza in the 2019-2020 influenza season and heterogeneity in nonpharmaceutical and
13 pharmaceutical interventions show that we cannot assume the same effect will occur globally.
14 The US and Europe must promote the implementation and continuation of these measures in
15 order to prevent additional burden to healthcare systems due to influenza.

16 **Key words:** COVID-19, influenza, nonpharmaceutical intervention, vaccination, United States,
17 Europe

18 **Introduction**

19 The COVID-19 pandemic has altered almost every aspect of public health since its global
20 spread in early 2020. The impacts of COVID-19 continue to unfold and one such consequence is
21 the effect of the pandemic on seasonal respiratory pathogens like influenza. The similarities
22 between the transmission pathways and clinical manifestations of SARS-CoV-2 and influenza
23 lead to critical ecological, public health and clinical interactions (Solomon et al., 2020). As the

24 influenza season begins in temperate, northern hemisphere regions, there is a devastating surge
25 of COVID-19 in the US and Europe that is pushing healthcare capacity to its limits, leaving no
26 room for additional public health burden. On the other hand, reports of a curtailed 2019-2020 flu
27 season in the US and a suppressed 2020 flu season in southern hemisphere nations have provided
28 encouraging signs. With the competing forces of viral interactions, overlapping protective
29 behaviors and a single, limited healthcare capacity, it remains unclear what the upcoming winter
30 will bring for influenza.

31 To understand the impacts of COVID-19 on influenza, we first look retrospectively. By
32 the time SARS-CoV-2 transmission had become widespread in early 2020, the influenza season
33 in Europe was largely over (Boelle, 2020), but flu transmission in the US was still ongoing and
34 declined rapidly in March and April (CDC, 2020a). Some have proposed that the pandemic and
35 the ensuing nonpharmaceutical interventions led to this unexpected decrease in influenza
36 transmission (Olsen et al., 2020). However, the viral circulation in the 2019-2020 season and the
37 timing of nonpharmaceutical interventions make these impacts unclear.

38 Global case studies provide further evidence to assess the impacts of COVID-19 on
39 influenza transmission. The countries in the southern hemisphere, which typically experience
40 their influenza season in May-October, have reported drastically reduced influenza circulation in
41 2020 (Olsen et al., 2020). One possible explanation for this pattern is viral competition between
42 SARS-CoV-2 and influenza. This competition could occur through multiple mechanisms, such
43 as immune interactions, viral competition and a reduced susceptible pool due to isolation
44 (Nickbakhsh et al., 2019; Rohani et al., 2003). But the more likely explanation is the significant
45 behavioral and pharmaceutical interventions in place in these settings that are leading to this
46 dramatic effect on flu. Nonpharmaceutical interventions such as closures of non-essential

47 businesses, telework, restriction on gathering size, and mask-wearing have been key public
48 health tools for limiting the impact of the COVID-19 pandemic (Di Domenico et al., 2020; Haug
49 et al., 2020). Given the shared transmission route between SARS-CoV-2 and influenza, the same
50 protective behaviors could greatly limit influenza transmission (Cowling et al., 2020). In fact, far
51 less mitigation effort is required to control a low R_0 disease like flu ($R_0 = 1-2$), compared with a
52 high R_0 disease like COVID-19 ($R_0 = 2-5$). Additionally, increased influenza vaccination is
53 another tool that could reduce influenza burden. Global case studies examining this data can
54 shine light on how these factors have impacted or will impact influenza transmission.

55 To further our retrospective and prospective understanding of influenza dynamics during
56 the COVID-19 pandemic, we consider case studies across geographic regions. We analyze
57 influenza data from the 2019-2020 season to identify whether COVID-19 significantly impacted
58 influenza transmission in the US. Then, we present global data on mobility and vaccination, for
59 countries that have already avoided an influenza season in the Southern hemisphere and
60 countries that are in the midst of the influenza season in the Northern hemisphere.

61 **Methods**

62 *Intervention Analysis*

63 We tested whether the 2019-2020 influenza A season was statistically different from
64 expectations based on influenza seasons of prior years. We separate influenza A from influenza
65 B as the influenza B dynamics in 2019-2020 were extremely unusual, mostly occurring early in
66 the season before COVID-19 was a factor in the US, and this obscures comparison of influenza
67 data with prior seasons (Figure S1). We obtained surveillance data from the CDC for the 2015-
68 2016 through the 2019-2020 influenza seasons (Centers for Disease Control and Prevention,
69 2020). We calculated the influenza A ILI rate as % positive influenza A * ILI / Total visits. This

70 accounts for influenza-like illness cases, healthcare seeking, and influenza A virus circulation.
71 We used intervention analysis as implemented in the `CausalImpact` R package to build an
72 expectation for the 2019-2020 influenza season, based on the 2015-2016, 2016-2017, 2017-2018,
73 and 2018-2019 seasons as control data (Brodersen et al., 2015). The date of the intervention was
74 March 16, 2020, which is the same week as the COVID-19 National Emergency Declaration in
75 the US. This means that the pre-intervention period was 10/7/2019-3/16/2020, and the post-
76 intervention period was 3/23/2020-7/1/2020. We compare the expected 2019-2020 influenza A
77 season to the actual 2019-2020 influenza A season. We also gathered mobility data from
78 Safegraph to evaluate mobility in this timeframe in the US, shown in Figure S2 (Safegraph,
79 2020).

80 *Global intervention comparison*

81 We gathered global mobility data from Google mobility reports (Google, 2020). This represents
82 the effectiveness of non-pharmaceutical interventions for COVID-19 in reducing mobility. We
83 particularly evaluate mobility to retail and recreational locations compared to a pre-pandemic
84 baseline. We also gathered 2020 influenza vaccination data for uptake of influenza vaccination.
85 This was gathered from Reseau Sentinelles and IQVIA France, the CDC, and the Australian
86 Department of Health (CDC, 2020b; Hunt, 2020). As a case study, we compared Australia,
87 France, and the US, as they are westernized, large population countries with data available on
88 these two factors. Australia provides a retrospective example, as it experienced a suppressed
89 influenza season in May-October 2020. We also examined NPIs in other southern hemisphere
90 countries for support (Figure S3). France and the US provide prospective examples for
91 comparison.

92 **Results**

93 **The 2019-2020 influenza season in the US was not significantly impacted by COVID-19**

94 When examining influenza A dynamics and controlling for healthcare seeking, the dynamics of
95 the 2019-2020 influenza season were not significantly different from what was expected after
96 March 16 based on the 4 prior influenza seasons. It is necessary to isolate influenza A from
97 influenza B because influenza B cases occurred much earlier and at a higher rate than previous
98 years (Figure S1). The high, early influenza B peak makes the 2019-2020 season appear to be
99 very severe early in the season. It also makes comparing the tail of the season misleading: in
100 typical years influenza B becomes more prevalent at the end of the season resulting in a more
101 gradual tail, and its early decrease in 2019-2020 makes the tail of the 2019-2020 season appear
102 to drop more drastically than typical years. Examining just influenza A dynamics reveals similar
103 dynamics to previous years. This is supported by evaluating mobility data in the US in early
104 2020 (Figure S2). This demonstrates that mobility did not deviate from previous years until
105 April, when the influenza season had ended.

106 **Southern Hemisphere countries engaged in reduced mobility and increased vaccination**
107 **during the influenza season**

108 Mobility to retail and recreational locations in Australia was at 30-45% below baseline at the
109 start of the influenza season (Figure 1B). Similar reduced mobility patterns at the start of the
110 influenza season were observed in Chile, Argentina, and South Africa (Figure S3). All of these
111 countries have reported diminished influenza seasons (Olsen et al., 2020; PAHO
112 PHE/IHM/Influenza Team, 2020). Additionally, Australia reported a 36% increase in influenza
113 vaccine distribution in 2020.

114

115

116 **Participation of Northern Hemisphere countries in nonpharmaceutical interventions**
117 **remains variable during the early influenza season**

118 Mobility to retail and recreational locations at the start of the 2020-2021 influenza season was at
119 35-40% below baseline. Additionally, vaccine purchase data shows that influenza vaccine
120 distribution was 13% higher in 2020 than in previous years. Mobility to retail and recreational
121 locations in the US at the start of the 2020-2021 influenza season was only slightly below
122 baseline values. Additionally, the US reports an 11% increase in influenza vaccine distribution.
123 However, stark heterogeneities exist both spatially and demographically. The US state of Iowa
124 estimates a decline in vaccination across populations, with a 24 percentage points decline in
125 vaccination in the 65+ age group (Iowa Department of Public Health, 2020). Additionally, it is
126 estimated that vaccination coverage among Black, non-Hispanic children in the US is down 11
127 percentage points from last year (CDC, 2020b).

128 **Discussion**

129 Our study does not seek to identify causal or correlative links between influenza and COVID-19
130 dynamics. Instead, we seek to synthesize various lines of evidence that allow for careful
131 consideration of this relationship in the future. We have considered case studies to explore the
132 impact of the COVID-19 pandemic on influenza dynamics in northern and southern hemisphere
133 nations. We find that the 2019-2020 influenza season in the US was not significantly impacted
134 by COVID-19. We compare mobility and flu vaccine distribution data for Australia, France, and
135 the US. Australia provides an example of suppressed influenza epidemics, in which significantly
136 reduced decreased mobility and increased vaccine distribution was observed during the early part
137 of the influenza season. France appears to be similar to Australia, with reduced mobility and an

138 increase in influenza vaccination. The US, however, has mobility similar to pre-pandemic
139 baseline, and an increase in vaccination, with notable spatial and demographic heterogeneity.

140 Influenza surveillance in the US through November 30th shows lower rates of disease
141 compared to previous seasons (Centers for Disease Control and Prevention, 2020), and Europe
142 has reported only 5 sentinel-source positive specimens out of 8729 samples through December
143 6th (Figure S4, ECDC-WHO, 2020). Travel restrictions due to the pandemic may also limit the
144 introduction of influenza from other countries. This encouraging news must be balanced with
145 caution. Healthcare systems are stretched to capacity with current COVID-19 hospitalizations
146 topping 113,000 in the US and 140,000 in Europe, so we cannot afford additional burden from
147 influenza (which leads to hundreds of thousands of hospitalizations annually in the US and
148 Europe). Recent data also suggests that while the risk of testing positive for SARS-CoV-2 was
149 68% lower among influenza cases, the risk of severe outcomes, such as ICU admission or death,
150 were many-fold higher for coinfection cases than for either infection alone (Stowe et al., 2020).
151 Thus, though current flu numbers are fortunate, continued diligence and public health messaging
152 will be necessary to continue to suppress influenza cases.

153 The lessons of the COVID-19 pandemic must be heeded to prevent further devastation.
154 We must sustain efforts towards social distancing and mask wearing, which have been
155 definitively linked to reductions in respiratory disease transmission. We must continue
156 vaccination administration efforts while accommodating social distancing requirements to
157 prevent exacerbation of health disparities. We must not let hopeful news of suppressed epidemics
158 deter from a path of action and vigilance.

159
160

161 **Competing Interests**

162 The authors declare that they have no competing interests.

163 **Ethics Statement**

164 This study and use of the SafeGraph dataset was approved by the Georgetown-Medstar IRB with
165 study ID STUDY00003041.

166 **Acknowledgments**

167 We thank Reseau Sentinelles and IQVIA France for providing us access to flu vaccine sale data.
168 Research reported in this publication was supported by the National Institute Of General Medical
169 Sciences of the National Institutes of Health under Award Number R01GM123007. The content
170 is solely the responsibility of the authors and does not necessarily represent the official views of
171 the National Institutes of Health. We also acknowledge support from the PhRMA Foundation.

172 **References**

173 Boelle P et al. Excess cases of Influenza like illnesses in France synchronous with COVID19
174 invasion 2020.

175 Brodersen KH, Gallusser F, Koehler J, Remy N, Scott SL. Inferring causal impact using
176 bayesian structural time-series models. *Ann Appl Stat* 2015;9:247–74.
177 <https://doi.org/10.1214/14-AOAS788>.

178 CDC. FluView Summary ending on September 26, 2020. FluView 2020a.
179 <https://www.cdc.gov/flu/weekly/weeklyarchives2019-2020/Week39.htm>.

180 CDC. Weekly National Flu Vaccination Dashboard. Wkly Natl Flu Vaccin Dashboard 2020b.
181 <https://www.cdc.gov/flu/fluview/dashboard/vaccination-dashboard.html>.

182 Centers for Disease Control and Prevention. Weekly U.S. Influenza Surveillance Report 2020.
183 <https://www.cdc.gov/flu/weekly/index.htm>.

184 Cowling BJ, Ali ST, Ng TWY, Tsang TK, Julian CM. Impact assessment of non-pharmaceutical
185 interventions against COVID-19 and influenza in Hong Kong: an observational study 2020.
186 Di Domenico L, Pullano G, Sabbatini CE, Boëlle PY, Colizza V. Impact of lockdown on
187 COVID-19 epidemic in Île-de-France and possible exit strategies. *BMC Med* 2020;18:1–13.
188 <https://doi.org/10.1186/s12916-020-01698-4>.
189 ECDC-WHO. Primary Care Data. *Flu News Eur* 2020.
190 <https://flunewseurope.org/PrimaryCareData/SentinelVirologicalDetections>.
191 Google. Community Mobility Reports 2020. <https://www.google.com/covid19/mobility/>.
192 Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the
193 effectiveness of worldwide COVID-19 government interventions. *Nat Hum Behav* 2020;4.
194 <https://doi.org/10.1038/s41562-020-01009-0>.
195 Hunt G. Record flu vaccines in 2020 to protect Australians. *Dep Heal* 2020.
196 [https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/record-flu-vaccines-in-2020-](https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/record-flu-vaccines-in-2020-to-protect-australians)
197 [to-protect-australians](https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/record-flu-vaccines-in-2020-to-protect-australians).
198 Iowa Department of Public Health. Influenza Vaccine Data. Iowa Public Heal Track Portal 2020.
199 <https://tracking.idph.iowa.gov/Health/Immunization/Influenza-Vaccine/Influenza-Vaccine-Data>.
200 Nickbakhsh S, Mair C, Matthews L, Reeve R, Johnson PCD, Thorburn F, et al. Virus-virus
201 interactions impact the population dynamics of influenza and the common cold. *Proc Natl Acad*
202 *Sci U S A* 2019;116:27142–50. <https://doi.org/10.1073/pnas.1911083116>.
203 Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased
204 Influenza Activity During the COVID-19 Pandemic — United States, Australia, Chile, and
205 South Africa, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1305–9.
206 <https://doi.org/10.15585/mmwr.mm6937a6>.

207 PAHO PHE/IHM/Influenza Team. Weekly Influenza Report EW 49. 2020.

208 Rohani P, Green CJ, Mantilla-Beniers NB, Grenfell BT. Ecological interference between fatal
209 diseases. *Nature* 2003;422:885–8. <https://doi.org/10.1038/nature01542>.

210 Safegraph. Social Distancing Metrics dataset 2020.


211 Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 Era. *JAMA* 2020;324:1342–
212 3. <https://doi.org/10.7189/JOGH.10.011101>.

213 Stowe J, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, et al. Title: Interactions
214 between SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test
215 negative design. *MedRxiv* 2020:2020.09.18.20189647.


216 Zipfel C, Bansal S. Assessing the interactions between COVID-19 and influenza in the United
217 States. *MedRxiv Prepr Serv Heal Sci* 2020:1–13. <https://doi.org/10.1101/2020.03.30.20047993>.

218 **Figure 1.**

219 A



B



220

221 (A) The 2019-2020 influenza season in the US showed no significant impact of COVID-19
222 pandemic mitigation measures. The weekly influenza A incidence ratio (% positive for

223 influenza A * ILI cases/Total visits, black dots, data from CDC 2020a) compared to what
224 is expected based on the 4 prior influenza seasons (blue dashed line with shaded 95%
225 confidence interval). After the COVID-19 National Emergency declaration in the US
226 (gray line), the influenza epidemic did not deviate significantly from previous seasons.
227 (B) Mobility to retail and recreational locations compared to baseline in Australia (green),
228 France (orange), and the US (green), from Google Community Mobility reports (Google
229 2020). The lines represent the regional mean for each country, and the shaded region is
230 the standard error. Arrows indicate the typical start of the influenza season for each
231 region in the corresponding color.